MX421215B - ANTICUERPOS PARA USARSE EN EL TRATAMIENTO DE ENFERMEDADES ALÉRGICAS MEDIADAS POR IgE - Google Patents
ANTICUERPOS PARA USARSE EN EL TRATAMIENTO DE ENFERMEDADES ALÉRGICAS MEDIADAS POR IgEInfo
- Publication number
- MX421215B MX421215B MX2020004469A MX2020004469A MX421215B MX 421215 B MX421215 B MX 421215B MX 2020004469 A MX2020004469 A MX 2020004469A MX 2020004469 A MX2020004469 A MX 2020004469A MX 421215 B MX421215 B MX 421215B
- Authority
- MX
- Mexico
- Prior art keywords
- ige
- antibodies
- treatment
- allergic diseases
- mediated allergic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cell Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762579416P | 2017-10-31 | 2017-10-31 | |
| PCT/CN2018/112714 WO2019085902A1 (en) | 2017-10-31 | 2018-10-30 | Treating ige-mediated allergic diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2020004469A MX2020004469A (es) | 2020-09-07 |
| MX421215B true MX421215B (es) | 2025-02-10 |
Family
ID=66332803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020004469A MX421215B (es) | 2017-10-31 | 2018-10-30 | ANTICUERPOS PARA USARSE EN EL TRATAMIENTO DE ENFERMEDADES ALÉRGICAS MEDIADAS POR IgE |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11439682B2 (https=) |
| EP (1) | EP3703753A4 (https=) |
| JP (1) | JP7286665B2 (https=) |
| KR (1) | KR102859911B1 (https=) |
| CN (1) | CN111741768B (https=) |
| AU (1) | AU2018360999A1 (https=) |
| BR (1) | BR112020008488A2 (https=) |
| CA (1) | CA3079992A1 (https=) |
| IL (1) | IL277911B2 (https=) |
| MX (1) | MX421215B (https=) |
| TW (1) | TWI821209B (https=) |
| WO (1) | WO2019085902A1 (https=) |
| ZA (1) | ZA202002247B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240191000A1 (en) * | 2021-04-02 | 2024-06-13 | Oneness Biotech Co., Ltd. | High concentration antibody formulations |
| CN118119641A (zh) * | 2021-10-12 | 2024-05-31 | 联合生物制药股份有限公司 | Ige调节的疾病的治疗 |
| CN114028731B (zh) * | 2021-12-10 | 2024-01-26 | 固安翌光科技有限公司 | 腰部塑形光疗装置 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989006138A1 (en) | 1987-12-31 | 1989-07-13 | Tanox Biosystems, Inc. | UNIQUE ANTIGENIC EPITOPES ON IgE-BEARING B LYMPHOCYTES |
| US5252467A (en) | 1987-12-31 | 1993-10-12 | Tanox Biosystems, Inc. | Method of making antibodies to antigenic epitopes of IGE present on B cells but not basophil cell surface or secreted, soluble IGE |
| US5422258A (en) | 1987-12-31 | 1995-06-06 | Tanox Biosystems, Inc. | Methods for producing high affinity anti-human IgE-monoclonal antibodies which binds to IgE on IgEabearing B cells but not basophils |
| US5362643A (en) | 1989-06-21 | 1994-11-08 | Tanox Biosystems | Antibodies to epitopes present on membrane-bound but not secreted IGA |
| US5231026A (en) | 1987-12-31 | 1993-07-27 | Tanox Biosystems, Inc. | DNA encoding murine-human chimeric antibodies specific for antigenic epitopes of IgE present on the extracellular segment of the membrane domain of membrane-bound IgE |
| US5614611A (en) | 1987-12-31 | 1997-03-25 | Tanox Biosystems, Inc. | Humanized monoclonal antibodies binding to IgE-bearing B cells but not basophils |
| US5342924A (en) | 1987-12-31 | 1994-08-30 | Tanox Biosystems, Inc. | Extracellular segments of human ε immunoglobulin anchoring peptides and antibodies specific therefor |
| US5274075A (en) | 1987-12-31 | 1993-12-28 | Tanox Biosystems, Inc. | Newly identified human epsilon immunoglobulin peptides and related products |
| US5449760A (en) | 1987-12-31 | 1995-09-12 | Tanox Biosystems, Inc. | Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils |
| US5690934A (en) | 1987-12-31 | 1997-11-25 | Tanox Biosystems, Inc. | Peptides relating to the extracellular membrane-bound segment of human alpha chain |
| US5091313A (en) | 1988-08-05 | 1992-02-25 | Tanox Biosystems, Inc. | Antigenic epitopes of IgE present on B cell but not basophil surface |
| US5484907A (en) | 1989-06-21 | 1996-01-16 | Tanox Biosystems, Inc. | Nucleotides coding for the extracellular membrane-bound segment of IgA |
| US5260416A (en) | 1987-12-31 | 1993-11-09 | Tanox Biosystems, Inc. | Antigenic epitopes present on membrane-bound but not secreted IgE |
| US5089603A (en) | 1989-06-21 | 1992-02-18 | Tanox Biosystems, Inc. | Antigenic epitopes present on membrane-bound but not secreted iga |
| US5079344A (en) | 1989-06-21 | 1992-01-07 | Tanox Biosystems, Inc. | Antigenic epitopes present on membrane-bound but not secreted IgA |
| US5514776A (en) | 1987-12-31 | 1996-05-07 | Tanox Biosystems, Inc. | Peptides representing antigenic epitopes of dog IgE present on B cell but not basophil surface |
| US5254671A (en) | 1990-04-27 | 1993-10-19 | Tanox Biosystems, Inc. | Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor |
| US5292867A (en) | 1988-11-16 | 1994-03-08 | Tanox Biosystems, Inc. | Chimeric monoclonal antibodies which bind to the extracellular segment of the membrane-bound domain of a human membrane-bound immunoglobulin |
| GB8913737D0 (en) | 1989-06-15 | 1989-08-02 | Univ Birmingham | A novel anti-allergy treatment |
| US5310875A (en) | 1989-06-21 | 1994-05-10 | Tanox Biosystems, Inc. | Peptides corresponding to membrane-bound IgA |
| DK0493446T3 (da) | 1989-09-15 | 1997-08-11 | Tanox Biosystems Inc | Behandling af autoimmunsygdom. |
| SG70982A1 (en) | 1990-01-23 | 2000-03-21 | Tanox Biosystems Inc | Extracellular segments of human and immunoglobulin anchoring peptides and antibodies specific therefor |
| US5281699A (en) | 1990-06-01 | 1994-01-25 | Tanox Biosystems, Inc. | Treating B cell lymphoma or leukemia by targeting specific epitopes on B cell bound immunoglobulins |
| US5298420A (en) | 1990-08-03 | 1994-03-29 | Tanox Biosystems, Inc. | Antibodies specific for isotype specific domains of human IgM and human IgG expressed or the B cell surface |
| AU9016591A (en) | 1990-10-25 | 1992-05-26 | Tanox Biosystems, Inc. | Glycoproteins associated with membrane-bound immunoglobulins as antibody targets on B cells |
| SE9102808L (sv) | 1991-09-26 | 1993-03-27 | Lars T Hellman Inst F Immunolo | Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner |
| CN1167491A (zh) | 1994-10-25 | 1997-12-10 | 美国联合生物医学公司 | 用于治疗变态反应的合成IgE膜锚肽免疫原 |
| AU3515597A (en) | 1997-05-30 | 1998-12-30 | Tanox Biosystems, Inc. | Inhibition of antigen-specific ige production by antigen coupled to membrane igepetide |
| EP2361635A3 (en) | 2000-08-30 | 2011-09-14 | Pfizer Products Inc. | Anti IgE vaccines |
| AUPS158502A0 (en) | 2002-04-08 | 2002-05-16 | Dermcare-Vet Pty Ltd | Allergic dermatitis composition and method of treatment |
| EP1941275B1 (en) | 2005-09-29 | 2013-07-24 | Medimmune, Inc. | Method of identifying membrane lg specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells |
| WO2007131129A2 (en) | 2006-05-03 | 2007-11-15 | Guthrie Foundation For Education & Research | Immunoglobulin associated cell-surface determinants in the treatment of b-cell disorders |
| PT2132230E (pt) | 2007-03-22 | 2014-07-17 | Genentech Inc | Anticorpos apoptóticos anti-ige que se ligam ao ige ligado a membrana |
| US8460664B2 (en) * | 2009-02-25 | 2013-06-11 | Academia Sinica | Anti-CεmX antibodies capable of binding to human mIgE on B lymphocytes |
| WO2011066374A2 (en) * | 2009-11-24 | 2011-06-03 | Alder Biopharmaceuticals, Inc. | Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
| US9775921B2 (en) | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
| WO2011108008A2 (en) | 2010-03-04 | 2011-09-09 | Transgene Biotek Ltd. | Antibody for targeted induction of apoptosis, cdc and adcc mediated killing of cancer cells, tbl-cln1 |
| EP2838919A4 (en) * | 2012-04-20 | 2016-03-23 | Academia Sinica | ANTIBLE ANTIBODIES BINDING TO THE TRANSITION BETWEEN CH4 AND C EPSILON MX DOMAINS |
| PL2892927T3 (pl) * | 2012-09-07 | 2018-11-30 | Regeneron Pharmaceuticals, Inc. | Sposoby leczenia atopowego zapalenia skóry przez podawanie antagonisty IL-4R |
| JP6068582B2 (ja) * | 2015-08-07 | 2017-01-25 | アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ | Ｂリンパ球上のヒトｍＩｇＥに結合可能な抗ＣεｍＸ抗体 |
-
2018
- 2018-10-30 BR BR112020008488-3A patent/BR112020008488A2/pt unknown
- 2018-10-30 KR KR1020207014545A patent/KR102859911B1/ko active Active
- 2018-10-30 JP JP2020543683A patent/JP7286665B2/ja active Active
- 2018-10-30 WO PCT/CN2018/112714 patent/WO2019085902A1/en not_active Ceased
- 2018-10-30 CN CN201880084604.5A patent/CN111741768B/zh active Active
- 2018-10-30 MX MX2020004469A patent/MX421215B/es unknown
- 2018-10-30 EP EP18873803.3A patent/EP3703753A4/en active Pending
- 2018-10-30 CA CA3079992A patent/CA3079992A1/en active Pending
- 2018-10-30 IL IL277911A patent/IL277911B2/en unknown
- 2018-10-30 AU AU2018360999A patent/AU2018360999A1/en not_active Abandoned
- 2018-10-31 TW TW107138583A patent/TWI821209B/zh active
-
2020
- 2020-04-29 US US16/862,512 patent/US11439682B2/en active Active
- 2020-05-04 ZA ZA2020/02247A patent/ZA202002247B/en unknown
-
2022
- 2022-09-09 US US17/930,799 patent/US12083161B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3703753A1 (en) | 2020-09-09 |
| IL277911A (en) | 2020-11-30 |
| JP2021501213A (ja) | 2021-01-14 |
| US11439682B2 (en) | 2022-09-13 |
| CN111741768B (zh) | 2024-12-27 |
| MX2020004469A (es) | 2020-09-07 |
| EP3703753A4 (en) | 2021-08-18 |
| ZA202002247B (en) | 2022-01-26 |
| TW201929899A (zh) | 2019-08-01 |
| US20200297815A1 (en) | 2020-09-24 |
| BR112020008488A2 (pt) | 2020-10-20 |
| RU2020117749A (ru) | 2021-12-02 |
| JP7286665B2 (ja) | 2023-06-05 |
| KR20200110302A (ko) | 2020-09-23 |
| US12083161B2 (en) | 2024-09-10 |
| KR102859911B1 (ko) | 2025-09-16 |
| TWI821209B (zh) | 2023-11-11 |
| IL277911B2 (en) | 2025-07-01 |
| IL277911B1 (en) | 2025-03-01 |
| CN111741768A (zh) | 2020-10-02 |
| WO2019085902A1 (en) | 2019-05-09 |
| US20230100100A1 (en) | 2023-03-30 |
| CA3079992A1 (en) | 2019-05-09 |
| RU2020117749A3 (https=) | 2022-01-31 |
| AU2018360999A1 (en) | 2020-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY40476A (es) | Moléculas de anticuerpo que se unen a tim-3 y usos de las mismas | |
| CL2018002694A1 (es) | Moleculas de anticuerpos que se unen a lag-3 y usos de las mismas (divisional solicitud 201602112) | |
| CY1124787T1 (el) | Αντισωματα anti-gitr και μεθοδοι χρησης αυτων | |
| SA518400222B1 (ar) | أجسام مضادة لـ وتركيبات tim-3 | |
| MX2019015738A (es) | Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos. | |
| BR112016005816A2 (pt) | Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores | |
| BR112018067525A2 (pt) | anticorpos tendo especificidade para o btla e seus usos | |
| BR112018012929A2 (pt) | anticorpos anti-cd20/anti-cd3 biespecíficos para tratar leucemia linfoblástica aguda | |
| EA201692039A1 (ru) | ИММУНОГЛОБУЛИНЫ, СВЯЗЫВАЮЩИЕ ЧЕЛОВЕЧЕСКИЕ Vγ9Vδ2 Т-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ | |
| BR112019005139A2 (pt) | anticorpos anti-il-33 e usos dos mesmos | |
| MX2017015876A (es) | Moleculas de union a lag-3 y metodos de uso de las mismas. | |
| EA201791093A1 (ru) | Антитела к cd47, способы и применение | |
| BR112015027399A2 (pt) | ANTICORPOS ANTI-IGF-1R COM LIGAÇÃO DE FcRn ABOLIDA E SEU USO NO TRATAMENTO DE ENFERMIDADES VASCULARES OCULARES | |
| BR112017027549A2 (pt) | anticorpo para cd40 | |
| GT201300149A (es) | Proteinas de union al tnf-a | |
| BR112015021134A2 (pt) | conjugados de fármaco e anticorpo | |
| BR112014018471A2 (pt) | anticorpos anti-ige m1' e métodos para o seu uso | |
| BR112018072066A2 (pt) | moléculas de ligação específicas para fcgamariia e uso das mesmas | |
| BR112015030356A2 (pt) | métodos de tratamento de uma taupatia | |
| MX351127B (es) | Proteínas de unión al antígeno del receptor de oncostatina m. | |
| EA201790475A1 (ru) | Способы лечения системной красной волчанки с использованием доменного антитела против cd28 | |
| EA201991203A1 (ru) | Способы лечения ожирения антителами к angptl8 | |
| EA201892525A1 (ru) | Конструкции днк-антител для применения против pseudomonas aeruginosa | |
| BR112016028726A2 (pt) | métodos de tratamento de um paciente diagnosticado com diabetes tipo 1, métodos de redução, supressão, atenuação ou inibição de um ou mais sintomas associados com t1d, e métodos de tratamento de um paciente que está em risco de t1d | |
| UY36262A (es) | Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso |